Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves surgery in combination with postoperative (adjuvant) platinum-based chemotherapy where indicated. Preoperative (neoadjuvant) therapies offer certain theoretical benefits compared with adjuvant approaches, includin...
Saved in:
| Main Authors: | Nick Pavlakis, Ken O'Byrne, Elizabeth Ahern, Brett G M Hughes, Ben J Solomon, Rina Hui |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/6/e002248.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC)
by: Dario de Biase, et al.
Published: (2024-12-01) -
Case report: Innovative approach to esophageal cancer with right aortic arch: neoadjuvant immunotherapy and 3D reconstruction
by: Chengwen Luo, et al.
Published: (2025-01-01) -
Need for a paradigm shift in soil-transmitted helminthiasis control: Targeting the right people, in the right place, and with the right drug(s).
by: Paul M Emerson, et al.
Published: (2024-10-01) -
Right versus left thoracic approach esophagectomy for patients with neoadjuvant immunochemotherapy
by: Kexi Wang, et al.
Published: (2025-12-01) -
Introduction: Right Left Right
by: Stan SMITH, et al.
Published: (2006-10-01)